At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Deferasirox (ICL670)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Open Label, Dose Escalation Trial and a Six Month Extension to Explore the Safety and Efficacy of ICL670 in Patients With Iron Overload Resulting From Hereditary Hemochromatosis.
In Brief
A Phase 2 clinical trial evaluating Deferasirox (ICL670) for Iron Overload and Hereditary Hemochromatosis. Completed, enrolled 49 participants across 18 sites in 6 countries.
Detailed Summary
Brief Summary: This study was designed to explore a safe dose and characterize the preliminary safety and efficacy of ICL670 in adult patients with previously documented history of homozygous C282Y.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIron Overload, Hereditary Hemochromatosis
CountriesAustralia, Canada, France, Germany, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedNov 2006
Primary CompletionDec 2007
Study CompletionMar 2009
TodayJul 2026
First PostedNov 3, 2006
Enrollment StartAug 1, 2006
Primary CompletionDec 1, 2007
Study CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.7 years ago
Interventions
Deferasirox (ICL670)drug